
    
      This is a prospective, Phase II, single center, open-label study in a total of 200
      participants with histologically proven neuroendocrine tumor or other somatostatin receptor
      positive tumors. Eligible participants will undergo baseline assessments at enrollment. They
      will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Participants may receive a
      second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
    
  